投资者因据称未能披露合规问题和误导性陈述而起诉Humacyte。 Investors sue Humacyte over alleged failure to disclose compliance issues and misleading statements.

对Humacyte Inc.提起的集体诉讼称,该公司未能披露其Durham设施履约情况、林业发展局审查拖延和关于其前景的误导性陈述方面的问题。 A class action lawsuit against Humacyte, Inc. alleges the company failed to disclose issues with its Durham facility's compliance, FDA review delays, and misleading statements about its prospects. 遭受损失的投资者可以在2025年1月17日之前加入诉讼并申请成为主要原告。 Investors who suffered losses can join the lawsuit and apply to be lead plaintiff by January 17, 2025.